ReviewNeurosciences (Riyadh, Saudi Arabia)2024
Tumefactive demyelinating lesions: A literature review of recent findings.
Review in Neurosciences (Riyadh, Saudi Arabia), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Biopsy-proven tumefactive demyelinating lesions: a systematic review and meta-analysis.BMC neurology · 2026Pooled it
- Tumefactive Multiple Sclerosis Mimicking a High-Grade Glioma: A Case Report and Literature Review.Reports (MDPI) · 2026Article
- Clinical application ofFrontiers in neuroscience · 2026Article
- Challenges in the Diagnosis of Multiple Sclerosis: A Case Report.Acta medica Lituanica · 2026Article
- Multiplanar MRI approach to the differential diagnosis of central nervous system tumors and tumor-like lesions in patients with HIV: what radiologists need to know.Frontiers in medicine · 2026Review
- Tumefactive demyelinating lesions: a case report and literature review.BMC neurology · 2025Review
- Article
- Unusual Stroke-Like Presentation of Tumefactive Multiple Sclerosis in a 27-Year-Old Man.Cureus · 2025Article
- Case report of intracranial tumor with serum MOG-IgG positivity.Frontiers in immunology · 2025Article
- Case report: From misdiagnosis to timely detection: a clinical and imaging guide to neurological presentations of diffuse large B-cell lymphoma-insights from six cases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumefactive demyelinating lesion is a variant of multiple sclerosis that is a diagnostic challenge. Tumefactive demyelinating lesion requires extensive work-up as its clinical and radiological features are often indistinguishable from other central nervous system lesions, such as tumors. Diagnosis is further complicated by the increasing recognition that tumefactive demyelinating lesions can occur alongside, evolve into, or develop from numerous conditions other than multiple sclerosis, pointing to a possible overlapping etiology. We review herein relevant studies from 2017 onwards to provide a current view on the pathogenesis, clinical and imaging findings, novel diagnostic techniques for differential diagnoses, and management of tumefactive demyelinating lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.